T
GNOM icon

Transce3nd’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Transce3nd’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26
Closed -$885 – 552
2025
Q2 		$885 Hold
26
– – ﹤0.01% 1007
2025
Q1 		$835 Hold
26
– – ﹤0.01% 979
2024
Q4 		$1.02K Buy
+26
New +$1.09K ﹤0.01% 1209

Other funds holding GNOM

FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Transce3nd's GNOM Position: Q3 2025 in Review

Transce3nd sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q3 2025, closing a stake of 26 shares — an estimated $885 sold.

Transce3nd first reported a position in GNOM in Q4 2024 and held it in 3 quarters. The position peaked at $1.02K in Q4 2024. 43 funds tracked by Wall St. Rank hold GNOM as of Q3 2025.

  • Transce3nd reported no remaining Global X Genomics & Biotechnology ETF position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 26 Global X Genomics & Biotechnology ETF shares in Q3 2025, an estimated $885.
  • Transce3nd first reported a position in Global X Genomics & Biotechnology ETF in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Global X Genomics & Biotechnology ETF position peaked at $1.02K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.